Page last updated: 2024-11-12
levodione
Description
levodione: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
levodione : A member of the class of cyclohexanones that is cyclohexane-1,4-dionecarrying a gem-dimethyl group at position 2 and an additional methyl substituent at position 6 (the R-enantiomer). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
PubMed CID | 10176229 |
CHEBI ID | 86400 |
SCHEMBL ID | 774113 |
MeSH ID | M0478802 |
Synonyms (13)
Synonym |
[6r]-2,2,6-trimethyl-1,4-cyclohexanedione |
HVHHZSFNAYSPSA-ZCFIWIBFSA-N |
(-)-(6r)-2,2,6-trimethyl-1,4-cyclohexandione |
SCHEMBL774113 |
CHEBI:86400 |
(r)-2,2,6-trimethyl-1,4-cyclohexanedione |
levodione |
(6r)-2,2,6-trimethyl-1,4-cyclohexanedione |
(r)-2,2,6-trimethylcyclohexane-1,4-dione |
(6r)-2,2,6-trimethylcyclohexane-1,4-dione |
Q27159134 |
60046-49-3 |
DTXSID601335381 |
Roles (1)
Role | Description |
bacterial metabolite | Any prokaryotic metabolite produced during a metabolic reaction in bacteria. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (1)
Class | Description |
cyclohexanones | Any alicyclic ketone based on a cyclohexane skeleton and its substituted derivatives thereof. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (6)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |